Operator
Greetings. Welcome to the Champions Oncology Second Quarter Fiscal Year 2026 Earnings Call. [Operator Instructions] Please note, this conference is being recorded. I will now turn the conference over to your host, Rob Brainin, Chief Executive Officer.
Robert Brainin
CEO & Director
Good afternoon, and thank you for participating in our second quarter fiscal 2026 earnings call. I’m joined today by our CFO, David Miller. Before we begin, I’ll remind you that today’s remarks may include forward-looking statements. Actual results may differ materially, and more information can be found in our filings with the SEC.
Before we get into the quarter, I want to ground everyone in our 3 core goals for the year: one, deliver year-on-year revenue growth, scaling matters, and we can get margin leverage in our core TOS business as we grow; two, invest in our big growth levers, especially our data platforms, which opens the door to more strategic biopharma relationships; and three, stay fiscally disciplined, maintaining full year positive adjusted EBITDA and self-fund our growth without shareholder dilution.
These goals guide our priorities, our investments and our execution focus. We remain committed to them. And importantly, based on our year-to-date results and visibility into the second half of the year, we believe we are on track to deliver on all of these.
Turning to the broader environment. We continue to see gradual improvement across pharma and biotech budgets. Funding levels are not fully restored, but customer engagement and our opportunity pipeline generation are gradually improving relative to what we experienced over the last 1.5 years. As
